Efficacy and Safety of Escitalopram for Prevention of Depression Induced by Peg-Interferon in Hepatitis C Patients
Status:
Completed
Trial end date:
2007-10-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether the use of an antidepressant (escitalopram)
can prevent depressive episodes that appear during the treatment with peg-interferon and
ribavirin in patients with chronic hepatitis C.